Published 2 years ago

Medicare recipients to see premium cut — but not until 2023

Summary by Ground News

Medicare Part B premiums jumped by $22 a month, to $170.10, for 2022. The increase was in part because of the cost of the drug Aduhelm. The drug was approved despite weak evidence that it could slow the progression of Alzheimer's. Legal and operational hurdles prevented officials from adjusting the 2022 premium.

0 Articles

All

Left

Center

Right

Associated Press News

Medicare recipients to see premium cut — but not until 2023

WASHINGTON (AP) — Medicare recipients will get a premium reduction — but not until next year — reflecting what Health and Human Services Secretary Xavier Becerra said Friday was an

2 years ago·United States

Read Full Article

abc News

Medicare recipients to see premium cut — but not until 2023

Medicare recipients will get a premium reduction — but not until next year

2 years ago·United States

Read Full Article

Washington Times

Medicare recipients to see premium cut — but not until 2023

Medicare recipients will get a premium reduction - but not until next year - reflecting what Health and Human Services Secretary Xavier Becerra said Friday was an overestimate in costs of covering an expensive and controversial new Alzheimer’s drug.

2 years ago·United States

Read Full Article

MY Northwest

Medicare recipients to see premium cut — but not until 2023

WASHINGTON (AP) — Medicare recipients will get a premium reduction — but not until next year — reflecting what Health and Human Services Secretary Xavier Becerra said Friday was an overestimate in costs of covering an expensive and controversial new Alzheimer’s drug.Becerra’s statement said the 2022 premium should be adjusted downward but legal and operational hurdles prevented officials from doing that in the middle of the year. He did not say …

2 years ago·Tacoma, United States

Read Full Article

WPLG

Medicare recipients to see premium cut — but not until 2023

Medicare recipients will get a premium reduction — but not until next year — reflecting what Health and Human Services Secretary Xavier Becerra said Friday was an overestimate in costs of covering an expensive and controversial new Alzheimer's drug.Becerra’s statement said the 2022 premium should be adjusted downward but legal and operational hurdles prevented officials from doing that in the middle of the year. He did not say how much the premi…

2 years ago·Miami, United States

Read Full Article